Abstracts tagged "pain"

Abstract Number: 1215 • ACR Convergence 2022
Identifying a Pain Signature in Classical Ehlers-Danlos Syndrome: Preliminary Results from Questionnaires and Experimental Pain Testing
Marlies Colman, Inge De Wandele, Lies Rombaut, Delfien Syx, Fransiska Malfait and Jessica Van Oosterwijck, Ghent University, Ghent, Belgium
Background/Purpose: Chronic pain is one of the most common complaints of individuals with Ehlers-Danlos syndrome (EDS) and the effects of the existing therapeutical modalities are…
Abstract Number: 1641 • ACR Convergence 2022
Determination and Characterization of Patient Subgroups with Different Pain Progression in Hand Osteoarthritis
Coen van der Meulen¹, Lotte van de Stadt¹, Frits Rosendaal¹, Jos Runhaar² and Margreet Kloppenburg¹, ¹Leiden university medical center, Leiden, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands
Background/Purpose: Pain is central to hand osteoarthritis (OA). Previous studies reported stable mean pain levels on the short to midterm. Subgroups with different pain trajectories…
Abstract Number: 1896 • ACR Convergence 2022
Alkylresorcinol, a Biomarker for Whole Grain Intake, and Its Association with Osteoarthritis: The MOST Study
Juan-Pablo Zertuche¹, Gabriela Rabasa¹, Alice H. Lichtenstein², Nirupa R. Matthan², Michael Nevitt³, James Torner⁴, Cora E. Lewis⁵, Devyani Misra⁶ and David Felson¹, ¹Boston University, Boston, MA, ²Tufts University, Boston, MA, ³University of California at San Francisco, Orinda, CA, ⁴University of Iowa, Iowa City, IA, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶Beth Israel Deconess Medical Center, Boston, MA
Background/Purpose: Whole grains, particularly wheat, are an important source of dietary fiber in the US. By providing a fermentable source, whole grains can modify the…
Abstract Number: 2180 • ACR Convergence 2022
Transfer of Monoclonal ACPAs Induces Pain, Bone Loss and Tenosynovitis in Mice in a Peptidyl Arginine Deiminase-4 Dependent Manner
Akilan Krishnamurthy¹, Jitong Sun², Alexandra Circiumaru¹, Yogan Kisten¹, Koji Sakuraba³, Thuy Tran¹, Peter Damberg¹, Patrik Jarvoll¹, Li Lu¹, Katalin Sándor¹, Tunhe Zhou⁴, vivianne malmström¹, Camilla I. Svensson¹, Aase Hensvold¹, Anca Catrina¹, Lars Klareskog¹ and Bence Réthi¹, ¹Karolinska Institutet, Stockholm, Sweden, ²Karolinska Institutet, Solna, Sweden, ³Karolinska Institutet and Karolinska University Hospital, Fukuoka, Japan, ⁴Stockholm University, Stockholm, Sweden
Background/Purpose: The appearance of anti-citrullinated protein antibodies (ACPAs) in the circulation represents a major risk factor for developing rheumatoid arthritis (RA). Here we studied whether…
Abstract Number: 0211 • ACR Convergence 2021
Unsupervised Machine-learning Algorithms for the Identification of Clinical Phenotypes in the Osteoarthritis Initiative Database
David Demanse¹, László B. Tankó², Patrick Lustenberger³, Philipp Nikolaus³, Ilja Rasin³, Damian F. Brennan³, Franziska Saxer², Ronenn Roubenoff⁴, Sumehra Premji¹, Philip Conaghan⁵ and Matthias Schieker⁴, ¹Novartis Pharma AG, Basel, Switzerland, ²Novartis Institutes for Biomedical Research, Basel, Switzerland, ³IBM Switzerland AG, Zürich, Switzerland, ⁴Novartis Institutes for Biomedical Research, Basel, Switzerland, Basel, Switzerland, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Osteoarthritis (OA) is a chronic disabling disease, for which there are only limited treatment options. One major challenge in the development of effective treatment…
Abstract Number: 0732 • ACR Convergence 2021
Topical Rofecoxib for OA of the Knee
Bruce Register¹, Nancy Lane², Lee Simon³, John Newsam⁴, Edward Kisak⁴, Jed Pheneger⁵, John Galvin⁵, Jeffrey Klein⁶ and Marc Hochberg⁷, ¹BriOri BioTech, Inc., Newport Beach, CA, ²University of California Davis, Hillsborough, CA, ³SDG LLC, West Newton, MA, ⁴Tioga Research, Inc, San Diego, CA, ⁵Inotiv, Boulder, CO, ⁶Sinclair Research Center, Auxvasse, MO, Canada, ⁷University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Osteoarthritis remains a highly prevalent disease in the elderly, and there are currently no approved treatments that can modify the disease course. Currently, both…
Abstract Number: 1236 • ACR Convergence 2021
Pain in Patients with Rheumatoid Arthritis Who Did or Did Not Achieve Treatment Response Based on Improvement in Swollen Joints with Baricitinib Clinical Trials
Anthony Sebba¹, Duzhe Wang², Bochao Jia², Jason Troutt², Julie Birt², Amanda Quebe³ and Peter C Taylor⁴, ¹Division of Rheumatology, University of South Florida, Tampa, FL, ²Eli Lilly and Company, Indianapolis, IN, ³Eli Lilly and Company, Indanapolis, IN, ⁴University of Oxford, Oxford, United Kingdom
Background/Purpose: Baricitinib (BARI) is a Janus kinase (JAK)1/JAK2 inhibitor which provides improvements to clinical signs, symptoms, and patient-reported outcomes (PROs) in patients with rheumatoid arthritis…
Abstract Number: 1760 • ACR Convergence 2021
Long-term Opioid Use Among Patients with Systemic Lupus Erythematosus
Jesse Dabit¹, Maria Valenzuela-Almada², Mehmet Hocaoglu³, Sebastian Vallejo-Ramos¹, Shirley-Ann Osei-Onomah¹, Sara Achenbach¹, Cynthia Crowson⁴ and Ali Duarte-Garcia¹, ¹Mayo Clinic, Rochester, MN, ²Division of Rheumatology, Mayo Clinic, Rochester, MN, ³University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ⁴Mayo Clinic, Eyota, MN
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic condition that can be associated with both acute and chronic musculoskeletal pain as well as fibromyalgia. Opioids…
Abstract Number: 0229 • ACR Convergence 2021
The Effects of Self-efficacy on Fatigue and Pain Interference in Black Women with Systemic Lupus Erythematosus: The Role of Depression, Age, and Education
Cristina Drenkard¹, Kirk Easley¹, Gaobin Bao¹, Charmayne Dunlop-Thomas¹, Teresa Brady² and S Sam Lim³, ¹Emory University, Atlanta, GA, ²Clarity Consulting and Communications, Atlanta, GA, ³Department of Medicine, Division of Rheumatology, Emory University School of Medicine, Atlanta, GA
Background/Purpose: Fatigue and pain are pervasive symptoms that cause escalating distress in patients with SLE, particularly among Black women and other high-risk groups. While these…
Abstract Number: 0733 • ACR Convergence 2021
A New Wearable Transcutaneous Electrical Nerve Stimulation Device (actiTENS®) Is More Efficient and Better Tolerated Than Weak Opioids in the Treatment of Knee Osteoarthritis Pain
Emmanuel Maheu¹, Sandrine Soriot-Thomas², Eric Noël³, Hervé Ganry⁴, Eric Lespessailles⁵ and Bernard Cortet⁶, ¹Saint-Antoine Hospital, Paris, France, ²CHU Amiens Picardie, Amiens, France, ³Santy Orthopaedic Center, Lyon, France, ⁴Hergan Consulting 4U, Amiens, France, ⁵CH Orléans, ORLEANS, France, ⁶CHU Lille, Lille, France
Background/Purpose: Knee osteoarthritis (KOA) is a frequent disease for which therapeutic possibilities are limited. In current recommendations, the first-line analgesic is acetaminophen. However, its low…
Abstract Number: 1333 • ACR Convergence 2021
Guselkumab (TREMFYA®) Provides Consistent and Durable Pain Improvement in Patients with Active Psoriatic Arthritis: Results of 2 Phase 3, Randomized, Controlled Clinical Trials
Peter Nash¹, Lai-Shan Tam², Wen-Chan Tsai³, Ying-Ying Leung⁴, Daniel Furtner⁵, Shihong Sheng⁶, Yanli Wang⁶, May Shawi⁷, Alexa Kollmeier⁸, Jonathan Sherlock⁹ and Daniel Cua⁶, ¹Griffith University, Brisbane, Australia, ²Department of Medicine & Therapeutics, The Prince of Wales Hospital, The Chinese University of Hong Kong, Hong Kong, China (People's Republic), ³Janssen Research & Development, LLC, Kaohsiung City, Taiwan (Republic of China), ⁴Singapore General Hospital and Duke-NUS Medical School, Singapore, Singapore, ⁵Janssen, a division of Johnson & Johnson Pte. Ltd., Singapore, Singapore, ⁶Janssen Research & Development, LLC, Spring House, PA, ⁷Janssen Immunology Global Commercial Strategy Organization, Toronto, ON, Canada, ⁸Janssen Research & Development, LLC, La Jolla, CA, ⁹Janssen Research & Development, LLC and University of Oxford, Spring House, PA
Background/Purpose: Guselkumab (GUS), a targeted inhibitor of IL-23p19, demonstrated significant efficacy v placebo (PBO) in achieving ACR20 response at week (W) 24 in patients (pts)…
Abstract Number: 1901 • ACR Convergence 2021
Severe Foot Symptoms Are Associated with Mortality: The Johnston County Osteoarthritis Project
Yvonne Golightly¹, Carolina Alvarez¹, Marian Hannan², Lucy Gates³, Becki Cleveland⁴, Amanda Nelson¹ and Leigh Callahan⁵, ¹University of North Carolina at Chapel Hill, Chapel Hill, NC, ²Marcus Institute for Aging Research, Hebrew SeniorLife, Milton, MA, ³University of Southampton, Southampton, United Kingdom, ⁴Thurston Arthritis Research Center, University of North Carolina at Chapel Hill School of Medicine, Chapel Hill, NC, ⁵University of North Carolina Thurston Arthritis Research Center, Chapel Hill, NC
Background/Purpose: Foot symptoms (i.e., pain, aching, and stiffness [PAS]) are common in middle-aged to older adults and are linked to restricted physical activity, poorer physical…
Abstract Number: 0234 • ACR Convergence 2021
Impact of Early Pain Improvement on Patient-reported Outcomes in Patients with Psoriatic Arthritis: Results from a Phase 3 Trial
Louis Bessette¹, Beatriz Joven-Ibáñez², Carlo Selmi³, Naijun Chen⁴, Koji Kato⁵, Ralph Lippe⁶, Patrick Zueger⁷, Jayeshkumar Patel⁴ and Joseph Merola⁸, ¹Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ²University Hospital 12 de Octubre, Madrid, Spain, ³Humanitas Research Hospital and Humanitas University, Milan, Italy, ⁴AbbVie Inc., North Chicago, IL, ⁵AbbVie Inc, Shinagawa- Ku, Japan, ⁶AbbVie Deutschland GmbH & Co. KG, Berlin, Germany, ⁷AbbVie Inc., Mettawa, IL, ⁸Harvard Medical School, Brigham and Women’s Hospital, Boston, MA
Background/Purpose: Pain is a dominant feature of PsA and has been identified by the GRAPPA-OMERACT working group as a core disease domain. Its control is…
Abstract Number: 0738 • ACR Convergence 2021
Therapeutic Effects of Oral Chinese Patent Medicine on Knee Osteoarthritis
Weiheng Chen¹, Mengge Song¹, Yan Jia¹, Jigao Sun¹, Yan Zhao², Zhipeng Xue³, Qianglong Chen², xiangrong Zeng² and Chenchen Wang⁴, ¹The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China (People's Republic), ²2Wangjing Hospital, China Academy of Chinese Medical Sciences, Beijing, China (People's Republic), ³1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China;, Beijing, China (People's Republic), ⁴Tufts Medical Center, Boston, MA
Background/Purpose: Oral Chinese patent medicine (CPM) has been deemed to have analgesic and anti-inflammatory effects and is widely used as the first-line treatment for osteoarthritis…
Abstract Number: 1341 • ACR Convergence 2021
Ixekizumab Shows a Pattern of Pain Improvement in Patients with and Without Measurable Inflammation in Psoriatic Arthritis
Kurt de Vlam¹, Gaia Gallo², Philip Mease³, Proton Rahman⁴, Venkatesh Krishnan², David Sandoval², Chen Yen Lin², Danting Zhu², Rebecca Bolce² and Philip Conaghan⁵, ¹University Hospitals Leuven, Leuven, Belgium, ²Eli Lilly and Company, Indianapolis, IN, ³Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ⁴Department of Medicine, Eastern Health and Memorial University of Newfoundland, St John's, NL, Canada, ⁵Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: The efficacy of ixekizumab (IXE) and adalimumab (ADA) in patients with psoriatic arthritis (PsA) has been previously reported using ACR 50 and Psoriasis Area…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].